The development of cost-effective, simple, and reproducible tests for diabetes screening represents a priority of modern medicine in light of the increasing prevalence of diabetes mellitus. Besides fasting plasma glucose, the oral glucose tolerance test, and glycated hemoglobin A1c, several tests have been proposed, among them the assessment of skin fluorescence spectroscopy (SFS). This article comments on the article by Olson and coauthors published in this issue of Journal of Diabetes Science and Technology and comprehensively reviews related available information. Overall, SFS seems to represent an easy-to-use, noninvasive tool that adds value to existing tests for diabetes screening.
PeppaMUribarriJVlassaraH. Advanced glycoxidation. A new risk factor for cardiovascular disease? Cardiovasc Toxicol. 2002; 2 (4): 275–87.
3.
AhmedNThornalleyPJ. Advanced glycation endproducts: What is their relevance to diabetic complications?. Diabetes Obes Metab. 2007; 9 (3): 233–45.
4.
NinJWJorsalAFerreiraISchalkwijkCGPrinsMHParvingHHTarnowLRossingPStehouwerCD. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12-year follow-up study. Diabetes Care. 2011; 34 (2): 442–7.
5.
BrownleeM. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414 (6865): 813–20.
6.
TanKCChowWSAiVHMetzCBucalaRLamKS. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care. 2002; 25 (6): 1055–9.
7.
BrownleeMCeramiAVlassaraH. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988; 318 (20): 1315–21.
8.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329 (14): 977–86.
9.
Pop-BusuiRHermanWHFeldmanELLowPAMartinCLClearyPAWaberskiBHLachinJMAlbersJW; DCCT/EDIC Research Group. DCCT and EDIC studies in type 1 diabetes: Lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. 2010; 10 (4): 276–82.
10.
VlassaraHBucalaRStrikerL: Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 1994; 70 (2): 138–51.
11.
GradinaruDBorsaCIonescuCMarginaD: Advanced oxidative and glycoxidative protein damage markers in the elderly with type 2 diabetes. J Proteomics. 2013. Epub ahead of print.
SmitAJGerritsEG. Skin autofluorescence as a measure of advanced glycation endproduct deposition: A novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010; 19 (6): 527–33.
14.
NaRStenderIMMaLWulfHC. Autofluorescence spectrum of skin: Component bands and body site variations. Skin Res Technol. 2000; 6 (3): 112–117.
15.
SellDRNemetIMonnierVM: Partial characterization of the molecular nature of collagen-linked fluorescence: Role of diabetes and end-stage renal disease. Arch Biochem Biophys. 2010; 493 (2): 192–206.
16.
ConwayBNArodaVRMaynardJDMatterNFernandezSRatnerREOrchardTJ. Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. Diabetes Care. 2012; 35 (11): 2331–6.
17.
KesselLHougaardJLSanderBKyvikKOSorensenTILarsenM. Lens ageing as an indicator of tissue damage associated with smoking and non-enzymatic glycation- a twin study. Diabetologia. 2002; 45 (10): 1457–62.
18.
OlsonBPMatterNIEdigerMNHullELMaynardJD. Noninvasive skin fluorescence spectroscopy is comparable to hemoglobin A1c and fasting plasma glucose for detection of abnormal glucose tolerance. J Diabetes Sci Technol. 2013; 7 (4): 990–1000.
19.
MaynardJDRohrscheibMWayJFNguyenCMEdigerMN. Noninvasive type 2 diabetes screening: Superior sensitivity to fasting plasma glucose and A1C. Diabetes Care. 2007; 30 (5): 1120–4.
20.
TentolourisNLathourisPLontouSTzemosKMaynardJ: Screening for HbA1c-defined prediabetes and diabetes in an at-risk greek population: Performance comparison of random capillary glucose, the ADA diabetes risk test and skin fluorescence spectroscopy. Diabetes Res Clin Pract. 2013; 100 (1): 39–45.
21.
TheilKoefoed PHansenTLarsenMPedersenOLund-AndersenH. Lens autofluorescence is increased in newly diagnosed patients with NIDDM. Diabetologia. 1996; 39 (12): 1524–7.
22.
SmitAJSmitJMBotterblomGJMulderDJ. Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes. PLOS ONE. 2013. Forthcoming.
23.
MooyJMGrootenhuisPAde VriesHKostensePJPopp-SnijdersCBouterLMHeineRJ. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: The Hoorn Study. Diabetologia. 1996; 39 (3): 298–305.
24.
StirbanAPopAFischerAHeckermannSTschoepeD. Variability of skin autofluorescence measurement over 6 and 12 weeks and the influence of benfotiamine treatment. Diabetes Technol Ther. 2013. To be published.
25.
De Ranitz-GrevenWLKaasenbroodLPouckiWKHamerlingJBosDCVisserGHBiesmaDHBeulensJWde ValkHW. Advanced glycation end products, measured as skin autofluorescence, during normal pregnancy and pregnancy complicated by diabetes mellitus. Diabetes Technol Ther. 2012; 14 (12): 1134–9.
26.
StirbanANandreanSNegreanMKoschinskyTTschoepeD. Skin autofluorescence increases postprandially in human subjects. Diabetes Technol Ther. 2008; 10 (3): 200–5.
LutgersHLGerritsEGGraaffRLinksTPSluiterWJGansROBiloHJSmitAJ: Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia. 2009; 52 (5): 789–97.
29.
MeerwaldtRLinksTPGraaffRHoogenbergKLefrandtJDBaynesJWGansROSmitAJ. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia. 2005; 48 (8): 1637–44.
30.
GerritsEGLutgersHLKleefstraNGraaffRGroenierKHSmitAJGansROBiloHJ. Skin autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care. 2008; 31 (3): 517–21.
31.
LutgersHLGraaffRLinksTPUbink-VeltmaatLJBiloHJGansROSmitAJ. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care. 2006; 29 (12): 2654–9.
